ProfileGDS5678 / 1428124_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 76% 82% 83% 78% 77% 71% 74% 78% 77% 79% 80% 80% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1952377
GSM967853U87-EV human glioblastoma xenograft - Control 25.1903576
GSM967854U87-EV human glioblastoma xenograft - Control 35.8942582
GSM967855U87-EV human glioblastoma xenograft - Control 46.1800783
GSM967856U87-EV human glioblastoma xenograft - Control 55.4176178
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1373877
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4537871
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8274874
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3995178
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2964177
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.4792279
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7011380
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.6423380
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3337878